Clinician's Pocket Drug Reference 2008

Alendronate 31PRN; 1 Rotacap inhaled q4–6h. PO: 2–4 mg PO tid-qid. Neb: 1.25–5 mg (0.25–1mL of 0.5% soln in 2–3 mL of NS) tid-qid. Peds. Inhaler: 2 inhal q4–6h. PO:0.1–0.2 mg/kg/dose PO; max 2–4 mg PO tid; Neb: 0.05 mg/kg (max 2.5 mg) in2–3 mL of NS tid-qid Caution: [C, +] Disp: Tabs 2, 4 mg; XR tabs 4, 8 mg; syrup2 mg/5 mL; 90 mcg/dose met-dose inhaler; soln for neb 0.083, 0.5% SE: Palpitations,tachycardia, nervousness, GI upsetAlbuterol & Ipratropium (Combivent, DuoNeb) Uses: *COPD*Action: Combo of β-adrenergic bronchodilator & quaternary anticholinergicDose: 2 inhal qid; neb 3 mL q 6 h Caution: [C, +] Contra: Peanut/soybean allergyDisp: Met-dose inhaler, 18 mcg ipratropium & 103 mcg albuterol/puff; nebulizationsoln (DuoNeb) ipratropium 0.5 mg & albuterol 2.5 mg/3 mL 0.042%, 0.21%SE: Palpitations, tachycardia, nervousness, GI upset, dizziness, blurred visionAldesleukin [IL-2] (Proleukin) WARNING: Use restricted to pts w/ nlpulm & cardiac Fxn Uses: *Met RCC & melanoma* Action: Acts via IL-2 receptor;many immunomodulatory effects Dose: 600,000 IU/kg q8h × 14 dosesdays 1–5 and days 15–19 of 28-day cycle (FDA-approved dose/schedule for RCC);other schedules (eg, “high dose” 24 × 10 6 IU/m 2 IV q8h on days 1–5 & 12–16)Caution: [C, ?/–] Contra: Organ allografts Disp: Powder for recons 22 × 10 6 IU,when reconstituted 18 million int units/ mL = 1.1 mg/mL SE: Flulike synd(malaise, fever, chills), N/V/D, ↑ bilirubin; capillary leak synd w/ ↓ BP, pulmedema, fluid retention, & wgt gain; renal & mild hematologic tox (↓ HgB,plt,WBC), eosinophilia; cardiac tox (ischemia, atrial arrhythmias); neuro tox (CNSdepression, somnolence, delirium, rare coma); pruritic rashes, urticaria, & erythrodermacommon. Notes: Cont inf ↓ risk severe ↓ BP & fluid retentionAlefacept (Amevive) WARNING: Must monitor CD4 before each dose;w/hold if